Literature DB >> 14642437

Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum.

Sigurd D Süssmuth1, Hayrettin Tumani, Daniel Ecker, Albert C Ludolph.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease leading to progressive cell death of upper and lower motor neurons and reactive astrogliosis. Two proteins which may be relevant in this respect (tau and S100 beta) were studied in cerebrospinal fluid (CSF) next to routine parameters in 20 patients with sporadic ALS and 20 age-matched controls. Serum levels of creatine kinase (CK) were also determined to monitor the muscular involvement. S100 beta showed a significant decrease in CSF over the disease course (P=0.024). CSF tau as well as serum CK were elevated in 70% of the ALS patients. While highest CSF tau levels were found rather in the early disease stages, serum CK showed a shift of the peak values to several months later. Elevation of the CSF/serum albumin quotient occurred in 20% of the cases most likely representing a non-specific finding in ALS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642437     DOI: 10.1016/j.neulet.2003.09.018

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

Review 1.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

2.  Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.

Authors:  Antonio Scarafino; Eustachio D'Errico; Alessandro Introna; Angela Fraddosio; Eugenio Distaso; Irene Tempesta; Antonella Morea; Antonella Mastronardi; Rosaria Leante; Maddalena Ruggieri; Mariangela Mastrapasqua; Isabella Laura Simone
Journal:  J Neurol       Date:  2018-08-16       Impact factor: 4.849

Review 3.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

5.  CSF neurofilament protein analysis in the differential diagnosis of ALS.

Authors:  Thierry S Reijn; Wilson F Abdo; Helenius J Schelhaas; Marcel M Verbeek
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

6.  Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Petra Steinacker; Corinna Hendrich; Anne-Dorte Sperfeld; Sarah Jesse; Stefan Lehnert; Alice Pabst; Christine A F von Arnim; Felix M Mottaghy; Ingo Uttner; Hayrettin Tumani; Albert Ludolph; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2009-08-01       Impact factor: 3.575

7.  Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.

Authors:  Murray Grossman; Lauren Elman; Leo McCluskey; Corey T McMillan; Ashley Boller; John Powers; Katya Rascovsky; William Hu; Les Shaw; David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 8.  Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Authors:  Robert Bowser; David Lacomis
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

Review 9.  Glial biomarkers in human central nervous system disease.

Authors:  Gwenn A Garden; Brian M Campbell
Journal:  Glia       Date:  2016-05-26       Impact factor: 7.452

10.  S100 protein family and its application in clinical practice.

Authors:  F Sedaghat; A Notopoulos
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.